C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial
Michiel S. van der Heijden,Thomas Powles,Daniel P. Petrylak,Ronald de Wit,Andrea Necchi,Cora N. Sternberg,Nobuaki Matsubara,Hiroyuki Nishiyama,Daniel Castellano,Syed A. Hussain,Aristotelis Bamias,Georgios Gakis,Jae Lyun Lee,Scott T. Tagawa,Ulka N. Vaishampayan,Jeanny B. Aragon-Ching,Bernhard J. Eigl,Rebecca R. Hozak,Erik R Rasmussen,Meng Xia,Ryan Rhodes,Sameera R. Wijayawardana,Katherine M. Bell-McGuinn,Amit Aggarwal,Alexandra Drakaki +24 more
TL;DR: In this paper , the authors evaluated the association of immune and angiogenesis pathways, and molecular subtypes, with overall survival (OS) in advanced urothelial carcinoma (UC).
Journal Article
Chemotherapy for advanced urothelial tract tumors: the M-VAC regimen.
Journal ArticleDOI
Clinical outcomes and safety in men ≥ 75 and < 75 years with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide in the phase 3 PREVAIL trial.
Julie N. Graff,Giulia Baciarello,Andrew J. Armstrong,Celestia S. Higano,Peter Iversen,David Forer,Harry H. Mansbach,De Phung,Bertrand Tombal,Tomasz M. Beer,Cora N. Sternberg +10 more
TL;DR: This prespecified analysis evaluated the impact of age (≥ 75 vs < 75 years) on efficacy and safety in the phase 3 PREVAIL trial, which improved overall survival and radiographic progression-free survival in chemotherapy-naive men with mCRPC.
Journal ArticleDOI
A phase III, randomized, double-blind, placebo-controlled study of enzalutamide in men with nonmetastatic castration-resistant prostate cancer: Post-hoc analysis of PROSPER by prior therapy.
Ugo De Giorgi,Eleni Efstathiou,William R. Berry,H. Payne,Katarzyna Madziarska,Katharina Modelska,Xiaowei Guan,Jennifer Sugg,Joyce Steinberg,Cora N. Sternberg +9 more
TL;DR: In men with nmCRPC and rapidly rising PSA, ENZA treatment resulted in a clinically meaningful reduction in the risk of developing metastases or death irrespective of prior surgery, radiation, or bone-targeting therapy.
Journal ArticleDOI
Multicenter phase II study of every-2 week gemcitabine and paclitaxel as first-line chemotherapy in patients with advanced urothelial tract cancer
Fabio Calabrò,Cora N. Sternberg,Vito Lorusso,L. Frassinetti,Gerardo Rosati,Teodoro Sava,M. Guida,N. Giovannini,L. Manzione,E. Donato Di Paola,Silvia Alonso +10 more
TL;DR: Patients with transitional cell carcinoma of the urothelium are not always amenable to cisplatin based chemotherapy, and a 60% RR in patients with this condition is previously reported.